Malignant lymphoma is a tumor of the lymphopoietic system, and there have been many new advances in the treatment in recent years, but there are still many difficulties and challenges. According to the 2008 edition of NCCN lymphoma treatment guideline, combined with our clinical experience, we would like to put forward the following suggestions for the reference of our colleagues, especially for the primary hospitals and non-oncology physicians, which may be helpful. 1.Lymph node enlargement in lymphoma is painless and progressive, unless it produces pain by pressing on surrounding organs. For those who have long term fever, wasting and night sweats, they should be more alert to the possibility of lymphoma. Many extranodal lymphomas do not have superficial lymph node enlargement, but are the corresponding manifestation of extranodal organ invasion (e.g. skin, nasal cavity, bone, gastrointestinal tract, testis, breast, etc.), and tissue biopsy of the lesion should be emphasized. 3. NCCN guidelines still emphasize the need to obtain sufficient tumor tissue (intact lymph nodes), and exact pathological diagnosis and staging are essential for treatment. Fine needle aspiration cannot be used for the initial diagnosis of lymphoma; core needle biopsy is also not recommended. 4. All patients with NHL should have a bone marrow biopsy or aspiration before treatment to clarify whether there is bone marrow invasion. 5. NCCN 2008 guidelines added the requirement of routine testing for hepatitis B virus before chemotherapy (hepatitis C index testing is only required in high-risk individuals). Special cases should be treated with prophylactic antiviral therapy prior to chemotherapy or immunochemotherapy to lower the viral copy number to a safe range and reduce the risk of viral activation. 6. Consensus on PET or PET/CT examinations: at least 3 weeks of rest should be taken at the end of treatment before proceeding. Rest for 6-8 weeks after chemotherapy and 8-12 weeks after radiotherapy. For those with positive residual lesions, a biopsy should be taken again to clarify the nature of the lesion. 7.Diffuse large B-cell lymphoma: NCCN 2008 guidelines recommend first-line treatment with R-CHOP21, R-CHOP14, R-EPOCH. high dose therapy with autologous stem cell rescue (HDT/ASCR) is specified. The enhanced status of first-line therapy after achieving remission. 8, Gastric MALT lymphoma IE stage H. pylori positive patients are given only recognized anti-H. pylori antibiotic therapy with re-staging and endoscopic follow up at 3 months. 9, Peripheral T-cell lymphoma has strong heterogeneity, there is no sure effective treatment, in principle, according to the principles of aggressive NHL treatment. nCCN 2008 guidelines recommend the first choice of clinical trials, after which the choice is chemotherapy. First-line chemotherapy includes CHOP, EPOCH and HyperCVAD/MTX-AraC. 10. Treatment of relapsed refractory NHL: There is no standard protocol yet. First, salvage chemotherapy such as GDP, GROC, DHAOx program, multiple relapses optional PEP-C, GND program is more efficient. Second, the clinical application of certain new drugs such as bortezomib, thalidomide, vorinostat, mTOR inhibitors, etc. Thirdly, molecular targeted therapy such as various monoclonal antibodies (anti-CD20, CD22, CD52, etc.), radiation immunotherapy (90Y-CD22 monoclonal antibodies), etc. Fourth is hematopoietic stem cell transplantation therapy, including autologous hematopoietic stem cell transplantation (AHSCT), AHSCT combined with targeted therapy, combined radioimmunotherapy, and allogeneic hematopoietic stem cell transplantation.